Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$57.1M |
| 2 |
Veralto
VLTO
|
+$54.6M |
| 3 |
Newmont
NEM
|
+$40.4M |
| 4 |
Vertiv
VRT
|
+$17.2M |
| 5 |
Webster Financial
WBS
|
+$14.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$314M |
| 2 |
ATVI
Activision Blizzard
ATVI
|
+$237M |
| 3 |
Microsoft
MSFT
|
+$231M |
| 4 |
VMW
VMware, Inc
VMW
|
+$130M |
| 5 |
NVIDIA
NVDA
|
+$102M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.88% |
| 2 | Healthcare | 12.91% |
| 3 | Consumer Discretionary | 12.16% |
| 4 | Industrials | 9.38% |
| 5 | Communication Services | 8.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2001
Healthcare Services Group
HCSG
$1.43B
| $1.52M | ﹤0.01% |
146,163
-15,800
| -10% | -$158K |
|
2002
MarineMax
HZO
$1.15B
| $1.51M | ﹤0.01% |
38,900
-6,800
| -15% | -$215K |
|
|
VERV
2003
DELISTED
Verve Therapeutics
VERV
| $1.51M | ﹤0.01% |
108,500
+13,200
| +14% | +$164K |
|
2004
Bank First Corp
BFC
$1.74B
| $1.51M | ﹤0.01% |
17,417
-2,000
| -10% | -$165K |
|
2005
Anavex Life Sciences
AVXL
$316M
| $1.5M | ﹤0.01% |
161,500
-16,200
| -9% | -$112K |
|
2006
B&G Foods
BGS
$291M
| $1.5M | ﹤0.01% |
142,500
-16,200
| -10% | -$150K |
|
2007
CryoPort
CYRX
$750M
| $1.49M | ﹤0.01% |
96,300
-3,800
| -4% | -$49.7K |
|
|
PRSU
2008
Pursuit Attractions and Hospitality Inc
PRSU
$1.27B
| $1.49M | ﹤0.01% |
41,200
-4,100
| -9% | -$124K |
|
|
INVX
2009
Innovex International
INVX
$2.13B
| $1.49M | ﹤0.01% |
64,000
-7,400
| -10% | -$174K |
|
2010
Arcturus Therapeutics
ARCT
$216M
| $1.49M | ﹤0.01% |
47,200
-5,400
| -10% | -$128K |
|
|
SII
2011
Sprott
SII
$3.03B
| $1.48M | ﹤0.01% |
43,575
-5,400
| -11% | -$167K |
|
2012
Hovnanian Enterprises
HOV
$793M
| $1.48M | ﹤0.01% |
9,500
-900
| -9% | -$90.5K |
|
2013
Heritage Financial
HFWA
$1.22B
| $1.48M | ﹤0.01% |
69,068
-8,100
| -10% | -$147K |
|
2014
Zentalis Pharmaceuticals
ZNTL
$307M
| $1.48M | ﹤0.01% |
97,400
-11,000
| -10% | -$160K |
|
2015
Kura Oncology
KURA
$882M
| $1.47M | ﹤0.01% |
102,400
-19,700
| -16% | -$194K |
|
2016
Liberty Live Group Series A
LLYVA
$9.45B
| $1.47M | ﹤0.01% |
+40,276
| New | +$1.34M |
|
2017
REX American Resources
REX
$1.44B
| $1.47M | ﹤0.01% |
62,200
-6,400
| -9% | -$128K |
|
|
INBX
2018
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $1.47M | ﹤0.01% |
38,700
-18,900
| -33% | -$405K |
|
2019
Portillo's
PTLO
$345M
| $1.47M | ﹤0.01% |
92,300
-10,400
| -10% | -$161K |
|
|
OSG
2020
Octave Specialty Group
OSG
$210M
| $1.47M | ﹤0.01% |
89,200
-9,400
| -10% | -$131K |
|
2021
First Mid Bancshares
FMBH
$1.38B
| $1.47M | ﹤0.01% |
42,400
+1,800
| +4% | +$54.3K |
|
2022
Editas Medicine
EDIT
$436M
| $1.47M | ﹤0.01% |
144,800
-34,400
| -19% | -$302K |
|
2023
Insteel Industries
IIIN
$635M
| $1.47M | ﹤0.01% |
38,300
-4,500
| -11% | -$149K |
|
2024
International Money Express
IMXI
$343M
| $1.46M | ﹤0.01% |
66,300
-9,800
| -13% | -$188K |
|
2025
Gray Television
GTN
$498M
| $1.46M | ﹤0.01% |
163,400
-18,400
| -10% | -$137K |
|
Similar funds
Swiss National Bank's Q4 2023 Portfolio in Review
As of Q4 2023, Swiss National Bank held 2,646 positions worth $136B, up 6.9% from $127B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Swiss National Bank withdrew a net $4.96B in Q4 2023, closing 112 positions and reducing 2,341 holdings. Its most notable exit was Activision Blizzard, an estimated $237M position sold in full.
By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 29% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Swiss National Bank opened a new position in Veralto worth $60.2M.
- Swiss National Bank's largest Q4 2023 buy was Veralto: 731,669 shares worth $60.2M.
- Swiss National Bank added most to Broadcom in Q4 2023, an estimated $57.1M increase.
- Swiss National Bank's biggest Q4 2023 reduction was Apple, cutting an estimated $314M.
- Swiss National Bank fully exited Activision Blizzard in Q4 2023, selling an estimated $237M.
- Swiss National Bank's ten largest holdings make up 28% of its $136B portfolio in Q4 2023.
- Swiss National Bank opened 38 new positions and closed 112 in Q4 2023.
- Swiss National Bank's portfolio value rose 6.9% quarter-over-quarter to $136B.
Based on Swiss National Bank's 13F filing for Q4 2023, filed 6 Feb 2024.